ProQR Therapeutics (PRQR) Cash from Financing Activities (2013 - 2026)
ProQR Therapeutics (PRQR) posted quarterly Cash from Financing Activities of -$345938.1 for Q1 2026, up 39.2% year-on-year from -$248518.7 in Q1 2025, and up 49.25% on a QoQ basis from -$681634.6 in Q4 2025.
ProQR Therapeutics (PRQR) Cash from Financing Activities (2013 - 2026) Analysis & Trends
ProQR Therapeutics (PRQR) has reported Cash from Financing Activities for 14 consecutive years, with -$345938.1 the latest figure, recorded in Q1 2026.
- Quarterly Cash from Financing Activities rose 39.2% year-over-year to -$345938.1 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.9 million (down 102.34% YoY) and the FY2025 annual result came in at -$2.1 million, down 102.61% from the prior year.
- Cash from Financing Activities rose to -$345938.1 in Q1 2026 per PRQR's latest filing, from -$681634.6 in the prior quarter.
- Over the last five years, Cash from Financing Activities for PRQR reached as high as $81.3 million in Q4 2024 and fell as low as -$49.8 million in Q3 2022.
- A 5-year average of $2.3 million and a median of -$476802.8 in 2024 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities slumped 285.7% — and 2024, when it surged 6641.21%.
- Year by year, Cash from Financing Activities stood at $15.7 million in 2022, then plunged by 107.93% to -$1.2 million in 2023, then soared by 6641.21% to $81.3 million in 2024, then sank by 100.84% to -$681634.6 in 2025, then jumped by 49.25% to -$345938.1 in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered -$345938.1, -$681634.6, and -$505251.7 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | ProQR Therapeutics | 219.53 Mn | 175.72 Mn | - | -345,938.10 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -345,938.10 |
| Mar 31, 2026 | -345,938.10 |
| Dec 31, 2025 | -681,634.61 |
| Dec 31, 2025 | -681,634.61 |
| Sep 30, 2025 | -505,251.70 |
| Sep 30, 2025 | -505,251.70 |
| Jun 30, 2025 | -333,420.60 |
| Jun 30, 2025 | -333,420.60 |
| Mar 31, 2025 | -568,977.14 |
| Mar 31, 2025 | -568,977.14 |
| Dec 31, 2024 | 81.28 Mn |
| Dec 31, 2024 | 81.28 Mn |
| Sep 30, 2024 | -515,493.28 |
| Sep 30, 2024 | -515,493.28 |
| Jun 30, 2024 | -320,903.10 |
| Jun 30, 2024 | -320,903.10 |
| Mar 31, 2024 | -476,802.84 |
| Mar 31, 2024 | -476,802.84 |
| Dec 31, 2023 | -1.24 Mn |
| Dec 31, 2023 | -1.24 Mn |